Opendata, web and dolomites

ELDICO ED SIGNED

ELDICO ED, Shaping the Future of Crystallography - The First Pure Electron Diffraction Equipment for Nano-Crystallography

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ELDICO ED project word cloud

Explore the words cloud of the ELDICO ED project. It provides you a very rough idea of what is the project "ELDICO ED" about.

incorporating    diffractometer    minimum    patenting    ray    segment    screened    unmeasurable    compounds    500k    pure    310m    designed    forecast    approval    m2    pharmaceutical    discovery    opening    2022    patent    3d    saving    crystallographers    diffraction    particles    perform    90    nanomaterials    atomic    nano    quality    techniques    marketing    generating    instruments    limited    compound    faster    roi    11    84    pharma    ed    investigations    annum    exclusively    eldico    micro    industry    unlocking    first    crystal    technique    regime    2024    solid    structure    crystalline    3m    substances    overcomes    agrochemicals    lower    commercial    sectors    structural    electron    time    institutes    issue    company    scientific    conventional    market    employees    overcoming    hitherto    sub    10    18bn    size    drug    mu    drugs    consuming    15    libraries    limitations    revenues    impossible    25    entering    shortening    pending    characterisation    measured   

Project "ELDICO ED" data sheet

The following table provides information about the project.

Coordinator
ELDICO SCIENTIFIC AG 

Organization address
address: PARK INNOVAARE DELIVERY LAB
city: VILLIGEN
postcode: 5234
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELDICO SCIENTIFIC AG CH (VILLIGEN) coordinator 50˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Crystal structure determination is still a key issue in pharmaceutical industry. Any compound requires its 3D atomic structure to become “fully characterized” for patenting and marketing approval. However, only the structure of the 10% of all crystalline substances can be determine. The reason: Conventional X-ray diffraction methods are limited because they require crystal of a minimum size of 10 x 10 μm2 and high quality to be measured, which are often time consuming or even impossible to produce. For example in drug discovery the 90% of known, but not fully characterized crystalline compounds, could be rapidly screened for their scientific or commercial potential. Although electron diffraction technique overcomes the limitations of current techniques and allows investigations on nano-crystalline systems, currently there are no commercial instruments dedicated exclusively to electron diffraction. With ELDICO ED we bring to the market the first equipment (patent pending) designed to perform electron diffraction. We offer an electron diffractometer for the analysis of solid compounds enabling crystallographers entering the sub-µm regime for structural analysis of hitherto unmeasurable nano-crystalline particles. That way, they produce important structural information faster, with better quality and at lower cost, overcoming the limitations of X-ray analysis. We are opening up a new market segment: Pure Electron Diffraction. Our technology will impact the pharma sector by unlocking the characterisation of the 500k existing potential new drugs in their libraries, shortening time-to-market by 10%, saving €9-18bn per annum for testing and increasing revenues of up to €310M per annum for every new drug that comes to the market. Similar impact in key sectors like research institutes, agrochemicals and Advanced Nanomaterials is expected. With ELDICO ED we forecast generating revenues of €25.3M (ROI: 11.84) and incorporating 15 employees to our company during 2022-2024

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ELDICO ED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ELDICO ED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

SiC-MOSFET (2019)

Gas Sensors for future Ultra Low NOx Emission Legislation – Euro 7

Read More  

IRMELI (2019)

AI-BASED BROKERING TECHNOLOGY PLATFORM TO FIND THE PERFECT MATCH BETWEEN THE CUSTOMER AND BANK

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More